{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:36:35Z","timestamp":1794015395763,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2018Y9205"],"award-info":[{"award-number":["2018Y9205"]}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2019Y9103"],"award-info":[{"award-number":["2019Y9103"]}]},{"name":"Joint Key Funds for the Health and Education of Fujian Province","award":["2019-WJ-23"],"award-info":[{"award-number":["2019-WJ-23"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bilateral breast cancer (BBC), as well as ovarian cancer, are significantly associated with germline deleterious variants in <jats:italic>BRCA1\/2<\/jats:italic>, while <jats:italic>BRCA1\/2<\/jats:italic> germline deleterious variants carriers can exquisitely benefit from poly (ADP-ribose) polymerase (PARP) inhibitors. However, formal genetic testing could not be carried out for all patients due to extensive use of healthcare resources, which in turn results in high medical costs. To date, existing <jats:italic>BRCA1\/2<\/jats:italic> deleterious variants prediction models have been developed in women of European or other descent who are quite genetically different from Asian population. Therefore, there is an urgent clinical need for tools to predict the frequency of <jats:italic>BRCA1\/2<\/jats:italic> deleterious variants in Asian BBC patients balancing the increased demand for and cost of cancer genetics services.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The entire coding region of <jats:italic>BRCA1\/2<\/jats:italic> was screened for the presence of germline deleterious variants by the next generation sequencing in 123 Chinese BBC patients. Chi-square test, univariate and multivariate logistic regression were used to assess the relationship between <jats:italic>BRCA1\/2<\/jats:italic> germline deleterious variants and clinicopathological characteristics. The R software was utilized to develop artificial neural network (ANN) and nomogram modeling for <jats:italic>BRCA1\/2<\/jats:italic> germline deleterious variants prediction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 123 BBC patients, we identified a total of 20 deleterious variants in <jats:italic>BRCA1<\/jats:italic> (8; 6.5%) and <jats:italic>BRCA2<\/jats:italic> (12; 9.8%). c.5485del in <jats:italic>BRCA1<\/jats:italic> is novel frameshift deleterious variant. Deleterious variants carriers were younger at first diagnosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.0003), with longer interval between two tumors (<jats:italic>P<\/jats:italic>\u2009=\u20090.015), at least one medullary carcinoma (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), and more likely to be hormone receptor negative (<jats:italic>P<\/jats:italic>\u2009=\u20090.006) and <jats:italic>HER2<\/jats:italic> negative (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). Area under the receiver operating characteristic curve was 0.903 in ANN and 0.828 in nomogram modeling individually (<jats:italic>P<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study shows the spectrum of the <jats:italic>BRCA1\/2<\/jats:italic> germline deleterious variants in Chinese BBC patients and indicates that the ANN can accurately predict BRCA deleterious variants than conventional statistical linear approach, which confirms the <jats:italic>BRCA1\/2<\/jats:italic> deleterious variants carriers at the lowest costs without adding any additional examinations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10160-y","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T09:16:34Z","timestamp":1667380594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical application of artificial neural network (ANN) modeling to predict BRCA1\/2 germline deleterious variants in Chinese bilateral primary breast cancer patients"],"prefix":"10.1186","volume":"22","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangmeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"10160_CR1","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2006.10.5056","volume":"25","author":"M Hartman","year":"2007","unstructured":"Hartman M, Czene K, Reilly M, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25:4210\u20136.","journal-title":"J Clin Oncol"},{"key":"10160_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-015-3538-5","volume":"153","author":"JJ Jobsen","year":"2015","unstructured":"Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H. Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res Treat. 2015;153:277\u201383.","journal-title":"Breast Cancer Res Treat"},{"key":"10160_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1471-2407-11-114","volume":"11","author":"S Alkner","year":"2011","unstructured":"Alkner S, Bendahl PO, Ferno M, Manjer J, Ryden L. Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer. 2011;11:114.","journal-title":"BMC Cancer"},{"key":"10160_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.breast.2011.09.007","volume":"21","author":"L Schwentner","year":"2012","unstructured":"Schwentner L, Wolters R, Wischnewsky M, Kreienberg R, Wockel A. Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast. 2012;21:171\u20137.","journal-title":"Breast"},{"key":"10160_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10549-010-1057-y","volume":"126","author":"EA Kheirelseid","year":"2011","unstructured":"Kheirelseid EA, Jumustafa H, Miller N, et al. Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat. 2011;126:131\u201340.","journal-title":"Breast Cancer Res Treat"},{"key":"10160_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/sj.bjc.6604898","volume":"100","author":"WH Kuo","year":"2009","unstructured":"Kuo WH, Yen AM, Lee PH, et al. Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer. 2009;100:563\u201370.","journal-title":"Br J Cancer"},{"key":"10160_CR7","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1200\/JCO.2011.35.0165","volume":"29","author":"AM Nichol","year":"2011","unstructured":"Nichol AM, Yerushalmi R, Tyldesley S, et al. A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes. J Clin Oncol. 2011;29:4763\u20138.","journal-title":"J Clin Oncol"},{"key":"10160_CR8","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/annonc\/mdh352","volume":"15","author":"J Rogozinska-Szczepka","year":"2004","unstructured":"Rogozinska-Szczepka J, Utracka-Hutka B, Grzybowska E, et al. BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. Ann Oncol. 2004;15:1373\u20136.","journal-title":"Ann Oncol"},{"key":"10160_CR9","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/ijc.32184","volume":"145","author":"M Deng","year":"2019","unstructured":"Deng M, Chen HH, Zhu X, et al. Prevalence and clinical outcomes of germline mutations in BRCA1\/2 and PALB2 genes in 2769 unselected breast cancer patients in China. Int J Cancer. 2019;145:1517\u201328.","journal-title":"Int J Cancer"},{"key":"10160_CR10","unstructured":"www.nccn.org\/NCCN guidelines insights: Genetic\/Familial high-risk assessment: breast, ovarian and pancreatic, version 2.2022."},{"key":"10160_CR11","doi-asserted-by":"crossref","unstructured":"Pohl-Rescigno E, Hauke J, Loibl S, et al. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. JAMA Oncol. 2020.","DOI":"10.1001\/jamaoncol.2020.0007"},{"key":"10160_CR12","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","volume":"3","author":"E Hahnen","year":"2017","unstructured":"Hahnen E, Lederer B, Hauke J, et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017;3:1378\u201385.","journal-title":"JAMA Oncol"},{"key":"10160_CR13","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1200\/JCO.2008.16.8310","volume":"26","author":"AW Kurian","year":"2008","unstructured":"Kurian AW, Gong GD, Chun NM, et al. Performance of BRCA1\/2 mutation prediction models in Asian Americans. J Clin Oncol. 2008;26:4752\u20138.","journal-title":"J Clin Oncol"},{"key":"10160_CR14","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.21.01647","volume":"40","author":"BH Ang","year":"2022","unstructured":"Ang BH, Ho WK, Wijaya E, et al. Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer. J Clin Oncol. 2022;40:1542\u201351.","journal-title":"J Clin Oncol"},{"key":"10160_CR15","doi-asserted-by":"publisher","first-page":"10229","DOI":"10.1038\/s41598-019-46707-6","volume":"9","author":"FH Hung","year":"2019","unstructured":"Hung FH, Wang YA, Jian JW, et al. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan. Sci Rep. 2019;9:10229.","journal-title":"Sci Rep"},{"key":"10160_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-022-01027-9","volume":"14","author":"J Liu","year":"2022","unstructured":"Liu J, Zhao H, Zheng Y, et al. DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data. Genome Med. 2022;14:21.","journal-title":"Genome Med"},{"key":"10160_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"10160_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10549-020-05573-x","volume":"180","author":"L Chen","year":"2020","unstructured":"Chen L, Fu F, Huang M, Lv J, Zhang W, Wang C. The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer. Breast Cancer Res Treat. 2020;180:759\u201366.","journal-title":"Breast Cancer Res Treat"},{"key":"10160_CR19","doi-asserted-by":"crossref","unstructured":"Bergmeir C, Ben\u00edtez JM. Neural Networks in R Using the Stuttgart Neural Network Simulator: RSNNS. ournal of Statistical Software. 2012 46(7):1\u201326.","DOI":"10.18637\/jss.v046.i07"},{"key":"10160_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"10160_CR21","unstructured":"SAS. http:\/\/www.sas.com."},{"key":"10160_CR22","unstructured":"IBM SPSS. http:\/\/www-01.ibm.com\/software\/uk\/analytics\/spss."},{"key":"10160_CR23","unstructured":"The R Project for Statistical Computing. https:\/\/www.r-project.org."},{"key":"10160_CR24","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980\u20135.","journal-title":"Nucleic Acids Res"},{"key":"10160_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST1 Sherry","year":"2001","unstructured":"Sherry ST1, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308\u201311.","journal-title":"Nucleic Acids Res"},{"key":"10160_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10689-014-9749-9","volume":"14","author":"Y Guan","year":"2015","unstructured":"Guan Y, Hu H, Peng Y, et al. Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing. Fam Cancer. 2015;14:9\u201318.","journal-title":"Fam Cancer"},{"key":"10160_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10549-016-3902-0","volume":"158","author":"J Zhang","year":"2016","unstructured":"Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. Breast Cancer Res Treat. 2016;158:455\u201362.","journal-title":"Breast Cancer Res Treat"},{"key":"10160_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ijc.30692","volume":"141","author":"GT Lang","year":"2017","unstructured":"Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int J Cancer. 2017;141:129\u201342.","journal-title":"Int J Cancer"},{"key":"10160_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10549-015-3377-4","volume":"151","author":"E Kang","year":"2015","unstructured":"Kang E, Seong MW, Park SK, et al. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015;151:157\u201368.","journal-title":"Breast Cancer Res Treat"},{"key":"10160_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12885-015-1516-2","volume":"15","author":"RI Dodova","year":"2015","unstructured":"Dodova RI, Mitkova AV, Dacheva DR, et al. Spectrum and frequencies of BRCA1\/2 mutations in Bulgarian high risk breast cancer patients. BMC Cancer. 2015;15:523.","journal-title":"BMC Cancer"},{"key":"10160_CR31","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun J, Meng H, Yao L, et al. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients. Clin Cancer Res. 2017;23:6113\u20139.","journal-title":"Clin Cancer Res"},{"key":"10160_CR32","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.24200","volume":"115","author":"MJ Hall","year":"2009","unstructured":"Hall MJ, Reid JE, Burbidge LA, et al. BRCA1andBRCA2mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222\u201333.","journal-title":"Cancer"},{"key":"10160_CR33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/tbj.12392","volume":"21","author":"S Bayraktar","year":"2015","unstructured":"Bayraktar S, Jackson M, Gutierrez-Barrera AM, et al. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J. 2015;21:260\u20137.","journal-title":"Breast J"},{"key":"10160_CR34","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/ijc.32877","volume":"146","author":"H Meng","year":"2020","unstructured":"Meng H, Yao L, Yuan H, et al. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients. Int J Cancer. 2020;146:3044\u201352.","journal-title":"Int J Cancer"},{"key":"10160_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/301670","volume":"62","author":"G Parmigiani","year":"1998","unstructured":"Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancersusceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145\u201358.","journal-title":"Am J Hum Genet"},{"key":"10160_CR36","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480\u201390.","journal-title":"J Clin Oncol"},{"key":"10160_CR37","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","volume":"91","author":"AC Antoniou","year":"2004","unstructured":"Antoniou AC, Pharoah PP, Smith P, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004;91:1580\u201390.","journal-title":"Br J Cancer"},{"key":"10160_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/cncr.24102","volume":"115","author":"KJ Ready","year":"2009","unstructured":"Ready KJ, Vogel KJ, Atchley DP, et al. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer. 2009;115:725\u201330.","journal-title":"Cancer"},{"key":"10160_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<857::AID-CNCR24>3.0.CO;2-Y","volume":"79","author":"HB Burke","year":"1997","unstructured":"Burke HB, Goodman PH, Rosen DB, et al. Artificial neural networks improve the accuracy of cancer survival prediction. Cancer. 1997;79:857\u201362.","journal-title":"Cancer"},{"key":"10160_CR40","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jhep.2009.12.037","volume":"52","author":"A Cucchetti","year":"2010","unstructured":"Cucchetti A, Piscaglia F, Grigioni AD, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol. 2010;52:880\u20138.","journal-title":"J Hepatol"},{"key":"10160_CR41","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/1097-0142(20010415)91:8+<1653::AID-CNCR1179>3.0.CO;2-B","volume":"91","author":"AM Ziada","year":"2001","unstructured":"Ziada AM, Lisle TC, Snow PB, Levine RF, Miller G, Crawford ED. Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. Cancer. 2001;91:1653\u201360.","journal-title":"Cancer"},{"key":"10160_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00432-019-03103-x","volume":"146","author":"X Qin","year":"2020","unstructured":"Qin X, Wang H, Hu X, Gu X, Zhou W. Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical information. J Cancer Res Clin Oncol. 2020;146:767\u201375.","journal-title":"J Cancer Res Clin Oncol"},{"key":"10160_CR43","doi-asserted-by":"crossref","unstructured":"Zhang X, Yang Y, Wang Y, Fan Q. Detection of the BRAF V600E Mutation in Colorectal Cancer by NIR Spectroscopy in Conjunction with Counter Propagation Artificial Neural Network. Molecules. 2019;24.","DOI":"10.3390\/molecules24122238"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10160-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10160-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10160-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T09:18:06Z","timestamp":1667380686000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10160-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10160"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10160-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by ethics committee of Fujian Medical University Union Hospital, written informed consent was obtained from all subjects before their participation. All the procedures performed in studies involving human participants adhere to The Code of Ethics of the World Medical Association (Declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1125"}}